EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Overview Fund Activity
Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

75 hedge funds and large institutions have $55.5M invested in Eagle Pharmaceuticals, Inc. in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 41 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
75
Holders Change
-16
Holders Change %
-17.58%
% of All Funds
1.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
11
Reduced
41
Closed
30
Calls
$5.66M
Puts
–
Net Calls
+$5.66M
Net Calls Change
+$5.85M

Top Buyers

1
Citigroup
Citigroup
New York
$5.61M
2
NCM
Nantahala Capital Management
Connecticut
$11M
3
PA
Perceptive Advisors
New York
$971K
4
RC
RBF Capital
California
$717K
5
CSS
Cubist Systematic Strategies
Connecticut
$145K

Top Sellers

1
BlackRock
BlackRock
New York
$1.98M
2
AQR Capital Management
AQR Capital Management
Connecticut
$3.9M
3
State Street
State Street
Massachusetts
$201K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
$0
5
Geode Capital Management
Geode Capital Management
Massachusetts
$605K
Name Holding Trade Value Shares
Change 		Shares
Change %
FFO
101
Fortitude Family Office
Arizona
– -$613 -117 Closed
NA
102
Nordwand Advisors
Pennsylvania
– -$524 -100 Closed
BC
103
Barrett & Company
Rhode Island
– -$524 -100 Closed
CFM
104
Catalyst Funds Management
Australia
– -$52 -10 Closed
AWM
105
Avior Wealth Management
Nebraska
– -$10 -2 Closed
1 2 3 4
5